Celator Pharmaceuticals Inc. (CPXX) was a publicly traded pharmaceutical company that specialized in developing treatments for cancer. The company was acquired by Jazz Pharmaceuticals plc (JAZZ) in July 2016 for $1.5 billion.
Celator was best known for its drug Vyxeos, a treatment for acute myeloid leukemia (AML), which was granted breakthrough therapy designation by the U.S. Food and Drug Administration (FDA) in 2016. Vyxeos combines two chemotherapy drugs, cytarabine and daunorubicin, in a single liposome formulation, which allows for a targeted delivery of the drugs to cancer cells.
The acquisition by Jazz Pharmaceuticals was seen as a major success for Celator, as it allowed the company to leverage Jazz's expertise in commercialization and sales to bring Vyxeos to market more quickly and effectively. The acquisition also represented a significant return for Celator's investors, who had supported the company through its development stages.
|
